Amgen (AMGN) debt: $54.6B
Amgen had $54.6B of long-term debt on Dec 31, 2025, including the part due within a year, down 9.1% from $60.1B a year earlier.
From Amgen's filings with the SEC · Read the filing · AMGN stock page
Amgen debt by year
#22 of 2,129 US companies by debt · See the full ranking
| Year ended | Debt | Change |
|---|---|---|
| Dec 31, 2025 | $54.6B | -9% |
| Dec 31, 2024 | $60.1B | -7% |
| Dec 31, 2023 | $64.6B | +66% |
| Dec 31, 2022 | $38.9B | +17% |
| Dec 31, 2021 | $33.3B | – |
Debt of similar companies
Companies in the same industry as Amgen, by SEC industry code, with the closest debt. Each name opens the same page for that company.
| Company | Debt, latest year | Year ended |
|---|---|---|
| Amgen | $54.6B | Dec 31, 2025 |
| Gilead Sciences | $24.9B | Dec 31, 2025 |
| Biogen | $6.3B | Dec 31, 2025 |
| Halozyme Therapeutics | $2.1B | Dec 31, 2025 |
| Qiagen | $1.7B | Dec 31, 2025 |
| Moderna | $590M | Dec 31, 2025 |
| Repligen | $542M | Dec 31, 2025 |
Questions and answers
What is Amgen's debt?
Amgen had $54.6B of long-term debt on Dec 31, 2025, including the part due within a year, down 9.1% from $60.1B a year earlier.
Numbers as reported in Amgen's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology